Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.12% $4.07
America/New_York / 13 feb 2024 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 181.50 mill |
EPS: | -1.340 |
P/E: | -3.03 |
Earnings Date: | Mar 08, 2024 |
SharesOutstanding: | 44.65 mill |
Avg Daily Volume: | 0.850 mill |
RATING 2024-02-13 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.03 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.52x |
Company: PE -3.03 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.99 - 4.13 ( +/- 1.65%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Yi Kathy | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Yi Kathy | Sell | 99 634 | Stock Option (Right to Buy) |
2024-02-14 | Stein Steven H | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Orbimed Advisors Llc | Sell | 650 600 | Common Stock |
2024-02-14 | Hayden Donald J Jr | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
-10.71 |
Last 94 transactions |
Buy: 24 821 782 | Sell: 19 785 944 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.07 (0.12% ) |
Volume | 0.678 mill |
Avg. Vol. | 0.850 mill |
% of Avg. Vol | 79.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:28 | sell | $4.08 | N/A | Active |
---|
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.